title: Left ventricular opacification after peripheral venous injection of a modified albumin solution.
abstract: The usefulness of a modified albumin solution was assessed in 8 dogs after peripheral venous and inferior vena cava injections. The contrast agent is a mixed solution made of glucose, albumin and glycerin, with sonicated microbubble diameter of 5.0 +/- 2.3 microns. Multiple injections (8 ml each) of this contrast agent (total 80 injections) into peripheral vein and inferior cava were performed. The blood pressure from femoral artery was measured before, during and after injections. Two-dimensional echocardiograms were recorded in a modified long axis view on videotapes for play back analysis. The pulmonary transit time and left ventricular contrast persistent time was determined for each injection. The videodensity of the region of interest (ROI) at the center of right ventricle and left ventricle was measured. The background videodensity of both ventricles was evaluated. The videodensity over the ROI of both ventricles with peak contrast enhancement was measured in all frames for 3 consecutive cardiac cycles. The peak videodensity of right and left ventricle subtracting the background videodensity of each ventricles was further calculated respectively. The injections caused no change in blood pressure or heart rate. All injections produced right ventricular contrast echo. As much as 85% of peripheral venous and 82.5% of inferior vena cava injections resulted in left ventricular contrast which was 0.68 and 0.65 as bright as that produced in the right ventricle. Pulmonary transit time and left ventricle contrast persistent time of peripheral venous injection was 4.05 +/- 0.53 and 13.67 +/- 4.28 seconds respectively. No difference of these data (3.93 +/- 0.47 and 11.65 +/- 4.66 seconds) from those produced by inferior vena cava injections were noted.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Internal Medicine, Veterans General Hospital, Koahsiung, Taiwan, Republic of China.
authors.forename: S L
authors.initials: SL
authors.lastname: Lin
authors.forename: J H
authors.initials: JH
authors.lastname: Lo
authors.forename: C Y
authors.initials: CY
authors.lastname: Mou
authors.forename: S J
authors.initials: SJ
authors.lastname: Ho
authors.forename: R H
authors.initials: RH
authors.lastname: Liu
authors.forename: J Y
authors.initials: JY
authors.lastname: Chan
authors.forename: M S
authors.initials: MS
authors.lastname: Chang
authors.forename: H T
authors.initials: HT
authors.lastname: Chiang
authors.forename: C Y
authors.initials: CY
authors.lastname: Chen
mesh_terms: D000418:Albumins / Q000008:administration & dosage* / Q000009:adverse effects; D000818:Animals; D003287:Contrast Media / Q000008:administration & dosage* / Q000009:adverse effects; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D004452:Echocardiography / Q000295:instrumentation / Q000379:methods*; D005947:Glucose / Q000008:administration & dosage / Q000009:adverse effects; D005990:Glycerol / Q000008:administration & dosage / Q000009:adverse effects; D006352:Heart Ventricles / Q000000981:diagnostic imaging; D007275:Injections, Intravenous; D012996:Solutions
chemical_list: D000418:Albumins; D003287:Contrast Media; D012996:Solutions; D005947:Glucose; D005990:Glycerol